

Seth E Karol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1491869/publications.pdf>

Version: 2024-02-01

71
papers

1,264
citations

471061

17
h-index

414034

32
g-index

71
all docs

71
docs citations

71
times ranked

2084
citing authors

#	ARTICLE	IF	CITATIONS
1	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015, 47, 607-614.	9.4	126
2	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	0.6	102
3	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	5.1	92
4	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease—Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	2.6	71
5	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	0.6	64
6	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019, 37, 2051-2061.	0.8	61
7	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	0.6	56
8	Genome-Wide Study Links <i>PNPLA3</i> Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 131-140.	2.3	50
9	Comparison of genome sequencing and clinical genotyping for pharmacogenes. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 380-388.	2.3	46
10	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 329-344.	5.7	44
11	Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 373-381.	2.3	40
12	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	0.8	38
13	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	1.2	31
14	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 622-637.	5.5	29
15	Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. <i>Blood</i> , 2006, 108, 2463-2469.	0.6	26
16	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1325-1332.	3.3	25
17	Predicting success of desensitization after pegaspargase allergy. <i>Blood</i> , 2020, 135, 71-75.	0.6	20
18	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	0.7	17
20	Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. <i>Cancer</i> , 2020, 126, 870-878.	2.0	17
21	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 541-551.	1.3	16
22	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
23	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092757.	1.1	13
24	Long-Term Functional Outcomes Among Childhood Survivors of Cancer Who Have a History of Osteonecrosis. <i>Physical Therapy</i> , 2020, 100, 509-522.	1.1	13
25	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0135134.	1.1	13
26	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 983-986.	0.6	12
27	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	2.0	12
28	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019, 134, 2649-2649.	0.6	12
29	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i> , 2017, 123, 3602-3608.	2.0	11
30	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27669.	0.8	11
31	Linkage analysis of neointimal hyperplasia and vascular wall transformation after balloon angioplasty. <i>Physiological Genomics</i> , 2006, 25, 286-293.	1.0	10
32	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 845540.	1.3	10
33	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e177-e181.	1.2	9
34	Pharmacogenomics and ALL treatment: How to optimize therapy. <i>Seminars in Hematology</i> , 2020, 57, 130-136.	1.8	9
35	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	0.8	8
36	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. <i>Blood</i> , 2020, 136, 37-38.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019, 14, e0216328.	1.1	7
38	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2020, 9, 6550-6555.	1.3	7
39	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28730.	0.8	7
40	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	2.3	7
41	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice. <i>Haematologica</i> , 2021, 106, 2095-2101.	1.7	6
42	Team approach: Management of osteonecrosis in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28509.	0.8	6
43	Whole-body joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28336.	0.8	6
44	Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29183.	0.8	6
45	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	0.6	6
46	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28244.	0.8	5
47	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 655-664.	1.1	5
48	Epidural blood patch for post-dural puncture headaches in adult and paediatric patients with malignancies: a review. <i>British Journal of Anaesthesia</i> , 2021, 126, 1200-1207.	1.5	5
49	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	1.7	5
50	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. <i>Blood</i> , 2020, 136, 30-31.	0.6	4
51	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. <i>International Journal for Quality in Health Care</i> , 2019, 31, 633-638.	0.9	3
52	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. <i>Blood</i> , 2020, 136, 2955-2958.	0.6	3
53	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	0.6	3
54	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. <i>Blood</i> , 2020, 136, 39-40.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. <i>Blood</i> , 2020, 136, 23-24.	0.6	3
56	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10004-10004.	0.8	3
57	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018, 132, 2697-2697.	0.6	2
58	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015, 126, 3714-3714.	0.6	2
59	Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26407.	0.8	1
60	Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29490.	0.8	1
61	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S177.	0.2	0
62	HLA Haplotype DRB1*07:01-DQA1*02:01-DQB1*02:02 Predicts Pegaspargase Hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB98.	1.5	0
63	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. <i>Blood</i> , 2013, 122, 490-490.	0.6	0
64	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 2295-2295.	0.6	0
65	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 3722-3722.	0.6	0
66	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 250-250.	0.6	0
67	Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy. <i>Blood</i> , 2018, 132, 4029-4029.	0.6	0
68	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2665-2665.	0.6	0
69	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	0.6	0
70	Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. <i>Blood</i> , 2020, 136, 11-12.	0.6	0
71	Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase. <i>Cancer Medicine</i> , 0, , .	1.3	0